Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
Lactulose, L-ornithine L-aspartate, or Rifaximin for HE Prophylaxis
NCT02158182Phase 4Completed
- Sponsor
- Hospital General de México "Dr. Eduardo Liceaga"
- Start
- Jul 2014
- Primary completion
- Jun 2016
- Modality
- Orthosteric Ligands, Metabolically Activated Prodrugs
- Countries
- 1
01
Overview
A Phase 4 trial of lactulose, l-ornithine l-aspartate, rifaximin in hepatic encephalopathy (HE), sponsored by Hospital General de México "Dr. Eduardo Liceaga". Started Jul 2014; status: completed.
02
Drugs
lactulosel-ornithine l-aspartaterifaximin
03
Conditions
hepatic encephalopathy (HE)
Beyond the preview
Go deeper on NCT02158182.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on NCT02158182.